Accolade, Inc. (NASDAQ:ACCD) Shares Bought by Barclays PLC

Barclays PLC raised its holdings in Accolade, Inc. (NASDAQ:ACCD) by 164.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 139,901 shares of the company’s stock after buying an additional 86,981 shares during the quarter. Barclays PLC owned about 0.17% of Accolade worth $539,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Mission Creek Capital Partners Inc. purchased a new position in shares of Accolade in the 3rd quarter valued at approximately $38,000. IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new position in Accolade during the 3rd quarter valued at approximately $46,000. Wolverine Trading LLC acquired a new position in Accolade during the 3rd quarter valued at approximately $51,000. Point72 Asia Singapore Pte. Ltd. raised its holdings in shares of Accolade by 1,144.1% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 20,913 shares of the company’s stock worth $81,000 after buying an additional 19,232 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in shares of Accolade during the third quarter worth $96,000. Institutional investors and hedge funds own 84.99% of the company’s stock.

Accolade Price Performance

Shares of NASDAQ ACCD opened at $6.89 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.72 and a quick ratio of 2.72. The stock has a market capitalization of $562.13 million, a price-to-earnings ratio of -3.06 and a beta of 2.08. The firm’s 50 day simple moving average is $4.08 and its 200-day simple moving average is $3.90. Accolade, Inc. has a 12 month low of $3.08 and a 12 month high of $13.93.

Accolade (NASDAQ:ACCD) last announced its quarterly earnings results on Friday, January 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.01. Accolade had a negative net margin of 18.16% and a negative return on equity of 18.43%. Analysts expect that Accolade, Inc. will post -0.92 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ACCD shares. Truist Financial downgraded Accolade from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 10th. Raymond James reissued a “market perform” rating on shares of Accolade in a report on Thursday, January 9th. Stifel Nicolaus reaffirmed a “hold” rating and set a $7.03 target price (down previously from $8.00) on shares of Accolade in a report on Thursday, January 9th. Morgan Stanley dropped their target price on Accolade from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 17th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Accolade in a research report on Wednesday, January 8th. Twelve analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $7.55.

Insider Transactions at Accolade

In other news, CEO Rajeev Singh sold 13,357 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $3.60, for a total transaction of $48,085.20. Following the transaction, the chief executive officer now owns 814,316 shares in the company, valued at $2,931,537.60. This trade represents a 1.61 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 41,298 shares of company stock valued at $149,987 in the last ninety days. 8.20% of the stock is currently owned by corporate insiders.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.